Lymphoma News

Women demonstrated a 34% increased risk for severe adverse events from any cancer treatment compared with men, according to a study published in Journal of Clinical Oncology.

The FDA has withdrawn approval of umbralisib for marginal zone lymphoma and follicular lymphoma due to safety concerns, according to an updated drug safety communication.

The FDA granted accelerated approval to tisagenlecleucel for treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

First-line therapy with axicabtagene ciloleucel induced objective responses in 89% of patients with high-risk large B-cell lymphoma, according to phase 2 study results.

First responders to the World Trade Center had higher rates of clonal hematopoiesis-associated mutations than firefighters not exposed to the dust, gases and potential carcinogens at the site, according to a study in Nature Medicine.

ASCO and the Association of Community Cancer Centers have jointly developed recommendations for improving equity, diversity and inclusion in cancer clinical trials.

Most patients with cancer demonstrated antibody responses to COVID-19 vaccination after two doses of the mRNA-1273 vaccine, according to an observational study published in JAMA Oncology.

The expansion of Medicaid under the Affordable Care Act correlated with an increase in 2-year OS rates among patients newly diagnosed with cancer, according to study results published in JNCI: Journal of the National Cancer Institute.

Black and Hispanic patients who received chimeric antigen receptor T-cell therapy for relapsed or refractory non-Hodgkin lymphoma achieved similar efficacy outcomes as white and Asian individuals, according to study results.

Black patients appeared consistently underrepresented in pivotal clinical trials that led to FDA approval of several chimeric antigen receptor T-cell therapies, according to findings published in JAMA Network Open.